![]() |
市場調查報告書
商品編碼
1359588
癌症支持治療藥物市場規模 - 按藥物類別、癌症類型、配銷通路、全球預測(2023 - 2032)Cancer Supportive Care Drugs Market Size - By Drug Class, Cancer type, Distribution Channel, Global Forecast (2023 - 2032) |
由於全球癌症發生率不斷上升,預計 2023 年至 2032 年癌症支持治療藥物市場規模的複合年成長率為 1.9%。根據美國癌症統計局的資料,2020年新增癌症病例超過150萬例,其中死亡人數近602,347人。隨著癌症病例數量持續增加,對減輕癌症治療副作用的療法(例如化療和放射療法)的需求正在激增。
此外,人們越來越意識到癌症治療期間生活品質的重要性,也推動了這些藥物的使用。隨著患者尋求控制症狀並保持更高水平的舒適度和幸福感的方法,癌症支持護理解決方案將獲得關注。
癌症支持治療藥物市場根據藥物類別、癌症類型、配銷通路和地區分類。
預計2023 年至2032 年,鴉片類藥物領域的複合年成長率將達到2.4% 左右。鴉片類藥物因其在控制癌症相關疼痛方面的有效性而聞名,因此越來越多的患者開始接受鴉片類藥物的治療。隨著鴉片類藥物配方的進步,重點已轉向實現最佳疼痛緩解,同時最大限度地減少副作用。這不僅提高了患者的舒適度,而且還提供了一種更全面的方法來管理癌症症狀。
肺癌領域預計在 2023 年和 2032 年期間複合年成長率為 2.5%,因為它是最受歡迎和最具侵襲性的癌症類型之一。肺癌患者常常會出現一系列令人痛苦的症狀,包括疼痛、呼吸困難和疲勞。因此,對針對肺癌患者特定需求的支持性護理藥物的需求很高。用於改善患者生活品質的肺癌創新藥物和療法的開發正在推動該行業的成長。
受惠於強大的醫療基礎設施、廣泛的研發活動和高癌症盛行率,北美癌症支持治療藥物產業預計 2023 年至 2032 年複合年成長率為 1.7%。美國和加拿大處於推動癌症支持治療的最前沿,大力投資研發,並確保患者能夠獲得最新、最有效的支持性治療藥物。北美對癌症治療期間患者舒適度和福祉的重視將繼續推動市場擴張。
Cancer supportive care drugs market size is predicted to witness 1.9% CAGR from 2023 to 2032 due to the escalating incidence of cancer worldwide. According to the data from the United States Cancer Statistics, more than 1.5 million new cancer cases were reported in 2020, out of which nearly 602,347 deaths were reported. As the number of cancer cases continues to rise, the demand for therapies that alleviate the side effects of cancer treatment, such as chemotherapy and radiation therapy, is surging.
Additionally, the growing awareness about the importance of quality of life during cancer treatment has fueled the usage of these drugs. As patients seek ways to manage their symptoms and maintain a higher level of comfort and well-being, the cancer support care solutions will gain traction.
Cancer supportive care drugs market is divided based on drug class, cancer type, distribution channel, and region.
The opioids segment is expected to record around 2.4% CAGR from 2023 to 2032. As opioids are known for their effectiveness in managing cancer-related pain, they are increasingly prescribed to patients undergoing cancer treatment. With advancements in opioid formulations, the focus has shifted toward achieving optimal pain relief while minimizing side effects. This is not only enhancing patient comfort but also providing a more comprehensive approach to managing cancer symptoms.
The lung cancer segment is anticipated to observe 2.5% CAGR during 2023 and 2032 as it is one of the most prevalent and aggressive types of cancer. Patients with lung cancer often suffer from a range of distressing symptoms, including pain, breathlessness, and fatigue. As a result, there is a high demand for supportive care drugs tailored to the specific needs of lung cancer patients. The development of innovative drugs and therapies for lung cancer for improving the quality of life for patients is driving the industry growth.
North America cancer supportive care drugs industry is expected to witness 1.7% CAGR from 2023 to 2032, favored by a robust healthcare infrastructure, extensive R&D activities, and high cancer prevalence. The United States and Canada are at the forefront of advancing cancer supportive care, investing heavily in R&D, and ensuring that patients have access to the latest and most effective supportive care drugs. The emphasis on patient comfort and well-being during cancer treatment in North America will continue to drive the market expansion.